Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT05244798Phase 3Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05244798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244798.